The Journey of Oseltamivir

Oseltamivir phosphate is an orally bioavailable prodrug of
oseltamivir carboxylate (OC). Oral bioavailability of the parent prodrug is approximately 75-80%
as the absorbed prodrug undergoes rapid first-pass hydrolysis by human carboxylesterase 1 (CES1)
in the small intestinal mucosa and liver to yield OC. Bioavailability of OC (the active species)
is approximately 79% based on comparative IV studies. Peak plasma concentrations of OC occur
within 3-4 hours after oral dosing. The drug is formulated as 30, 45, and 75 mg capsules and as
an oral suspension for pediatric use. Food does not significantly affect OC bioavailability but
may improve GI tolerability (nausea is a dose-limiting adverse effect). The formulation as an
ethyl ester (prodrug strategy) was specifically designed to overcome the poor oral bioavailability
of the parent carboxylate, which is too polar to be absorbed across the GI mucosa without the
ester mask. The prodrug approach also reduces GI irritation compared to the carboxylate.

Oseltamivir carboxylate (OC) distributes to the lung — the
primary site of influenza infection — with lung tissue concentrations at least equaling plasma
concentrations. Volume of distribution of OC is approximately 23-26 L, slightly exceeding plasma
volume and indicating some extravascular distribution. Plasma protein binding of OC is low at
approximately 3%, meaning the drug is essentially freely circulating in plasma with a high free
fraction available for antiviral activity. This minimal protein binding also means drug-drug
interactions via protein displacement do not occur. Oseltamivir carboxylate achieves concentrations
in nasal mucosa and middle ear fluid sufficient for antiviral activity. CNS concentrations are low
(OC is relatively polar), though there have been reports of neuropsychiatric events in Japanese
children, attributed to possible CNS access or to influenza itself.

Influenza neuraminidase (NA, sialidase) is a surface glycoprotein
that cleaves terminal sialic acid residues from the oligosaccharide chains on the host cell surface
and newly replicated virion hemagglutinin. This cleavage is essential for: (1) release of newly
formed virions from infected host cells (virions aggregate without NA activity), (2) preventing
self-aggregation of released virions, and (3) movement of the virus through respiratory mucus
(which contains sialic acid-rich mucins). Oseltamivir carboxylate is a conformationally rigid
analogue of the sialic acid transition state — it fits snugly into the highly conserved active
site of NA (both influenza A and B neuraminidases share conserved catalytic residues: Arg118,
Asp151, Arg152, Arg224, Glu276, Arg292, Arg371, Tyr406). OC binds competitively and potently
(Ki ~0.1 nM for N1; ~1 nM for N2), trapping newly assembled virions on the host cell surface
and dramatically reducing viral spread to uninfected cells.

The conversion of oseltamivir phosphate to oseltamivir carboxylate
(OC) is mediated primarily by carboxylesterase 1 (CES1, hCE1) in the liver and intestine. CES1
polymorphisms (particularly CES1*7, Q143H variant) can significantly reduce OC formation, leading
to lower plasma OC concentrations and potentially reduced antiviral efficacy — with pharmacogenomic
implications for high-risk patients. Once formed, OC is not further metabolized; it circulates
unchanged until renal excretion. Oseltamivir and OC are not substrates or inhibitors of CYP450
enzymes, and are not involved in P-glycoprotein transport. The absence of CYP interactions makes
oseltamivir essentially free of metabolic drug-drug interactions — a clinical advantage given that
influenza patients often receive multiple concurrent medications.

Oseltamivir carboxylate is excreted unchanged via the kidneys.
Renal clearance of OC (approximately 12.5 L/h) exceeds GFR, indicating active tubular secretion
via OAT1 and OAT3 transporters. Probenecid (an OAT inhibitor) approximately doubles OC plasma
AUC — used in some resource-limited settings to stretch oseltamivir supplies. The elimination
half-life of OC is approximately 6-10 hours in healthy adults, supporting twice-daily dosing for
treatment (75 mg twice daily for 5 days) and once-daily dosing for prophylaxis (75 mg/day for
10 days post-exposure). In severe renal impairment (CrCl 10-30 mL/min), OC AUC increases
approximately 3-fold, requiring dose reduction. Oseltamivir prophylaxis is approved for patients
down to 1 year of age; for neonates and very young infants, dosing is weight-based. Hemodialysis
removes OC; supplemental dosing after sessions is required.

Oseltamivir (Tamiflu) is the most widely used antiviral for
influenza A and B worldwide, approved for treatment and prophylaxis. In healthy adults, treatment
started within 48 hours of symptom onset reduces illness duration by approximately 1-1.5 days
and reduces risk of lower respiratory complications. In high-risk groups (elderly, immunocompromised,
severe influenza), treatment benefit is more substantial. Resistance occurs primarily through NA
mutations: H274Y (N1 numbering) — the most clinically important oseltamivir resistance mutation —
reduces oseltamivir binding >100-fold while maintaining NA enzymatic function. The 2009 H1N1
pandemic strains were initially largely resistant (H274Y), but subsequent reassortment restored
susceptibility. Zanamivir (inhaled) and IV peramivir are alternatives when oseltamivir resistance
or oral administration is an issue.